← Leaderboards
Gary Allan Ulaner
Hoag Memorial Hospital Presbyterian
$1,885,670
Attributed
$5,352,732
Total exposure
2
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.4M · FY2016–24$2M$1.5M$1M$500K$0
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$5,352,732 · 2
By mechanism
R01$5,352,732 · 2
Top collaborators
- Carl Ola Landgren6 shared
- Jason S Lewis5 shared
- Brian Matthew Zeglis5 shared
- Brian Agnew4 shared
Most similar at Hoag Memorial Hospital Presbyterian
Same institution · by research overlap
- Carl Ola Landgren$1,820,254
Others in their field
Top investigators on “Radiolabeled”
- Steven H Liang · Emory University$25,718,454
- Robert H Mach · Wake Forest University$24,553,580
- Oliver W. Press · Fred Hutchinson Cancer Research Center$18,336,602
- Michael Rod Zalutsky · Duke University$16,391,432
- Robert M Glickman · New York University School Of Medicine$15,401,672
- Steven Grant Deeks · University Of California Los Angeles$13,965,041
Research focus
RadiolabeledInvestigationAntibodiesDesignClinical CarePositron-Emission TomographyTumorImageImaging AgentSiteClinical TrialsUptakeSafetyCancer ImagingPatient ImagingFirst-In-HumanTranslationsBaseFluorodeoxyglucose Positron Emission TomographyBone Marrow BiopsyFunding OpportunitiesBlood TestsBlindFuture
Grant awards (11)
CD38-TARGETED IMMUNOPET OF MYELOMA: PHASE 2 TRIAL OF CLINICAL APPLICATIONS$560,238
R01 · FY2024 · CA · contact PI
CD38-TARGETED IMMUNOPET OF MYELOMA: PHASE 2 TRIAL OF CLINICAL APPLICATIONS$577,160
R01 · FY2023 · CA · contact PI
CD38-TARGETED IMMUNOPET OF MYELOMA: PHASE 2 TRIAL OF CLINICAL APPLICATIONS$50,000
R01 · FY2023 · CA · contact PI
CD38-TARGETED IMMUNOPET OF MYELOMA: PHASE 2 TRIAL OF CLINICAL APPLICATIONS$40,000
R01 · FY2022 · CA · contact PI
The Clinical PET Imaging of Metastatic Breast Cancer with Site-Specifically Labeled 89Zr-Trastuzumab$684,004
R01 · FY2020 · CA
CD38-TARGETED IMMUNOPET OF MYELOMA: PHASE 2 TRIAL OF CLINICAL APPLICATIONS$598,926
R01 · FY2020 · CA · contact PI
CD38-targeted immunoPET of myeloma: Phase 2 trial of clinical applications$135,622
R01 · FY2020 · CA · contact PI
The Clinical PET Imaging of Metastatic Breast Cancer with Site-Specifically Labeled 89Zr-Trastuzumab$679,482
R01 · FY2019 · CA
The Clinical PET Imaging of Metastatic Breast Cancer with Site-Specifically Labeled 89Zr-Trastuzumab$674,466
R01 · FY2018 · CA
The Clinical PET Imaging of Metastatic Breast Cancer with Site-Specifically Labeled 89Zr-Trastuzumab$667,617
R01 · FY2017 · CA
The Clinical PET Imaging of Metastatic Breast Cancer with Site-Specifically Labeled 89Zr-Trastuzumab$685,217
R01 · FY2016 · CA